Welcome to the Stocktwits Top 25 Newsletter for Week 07 of 2024!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.Β
Here are the Stocktwits Top 25 Lists for Week 07:
P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Standard and Poor's 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (+3.92%) outperformed the S&P 500 index (-0.42%).
There wereΒ 11 major changesΒ to the list this week.
In addition to the uptick in changes this week, we saw Stocktwits sentiment shift toward more neutral readings as market volatility picked up.
Check out how the momentum meter has performed vs. the S&P 500 index this year:
Your Market Edge Unleashed:
Unleash your potential with our Edge subscription planβbringing you unique social data, an ad-free experience, and more!
NASDAQ 100
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+29.40%) outperformed the Russell 2000 index (+1.13%).
There wereΒ 9 major changesΒ to the list this week.
Again, healthcare continues to dominate as investors look for the next big winners in the space. Like the other lists, we’re seeing a downtick in sentiment readings across the board.
πΆπΆπΆ
ST Top 25 TOP DAWG OF THE WEEK πΆ
The Top 25 lists’ Top Dawg was Sangamo Therapeutics Inc, which rallied 142.11%. π
The micro-cap biotech company is still running after the February 6th news, stating that its early phase 1/2 data shows ‘durable’ safety and efficacy of its Fabry disease drug candidate.
Additionally, investors continue to snap up these smaller names, hoping that larger healthcare companies will buy them to bolster their growth pipelines. π
$SGMO is up 155.56% YTD.